Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Biomed Biotechnol. 2010;2010:294582. doi: 10.1155/2010/294582. Epub 2010 Jun 28.

Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus.

Author information

  • 1Department of Internal Medicine, University Tor Vergata of Rome, 00133 Rome, Italy.

Abstract

Systemic Lupus Erythematosus (SLE) is an autoimmune disorder characterized by excessive production of a variety of autoantibodies and a wide range of clinical manifestations. Pathogenesis of SLE is complex and not fully understood. There is however evidence that B and T cells are critical to the development of disease, and that T cell-derived cytokines are involved in the SLE-associated inflammatory response. One such cytokine seems to be interleukin (IL)-21, the latest identified member of the gamma-chain-related cytokine family. IL-21 has an important role in the control of the growth, survival, differentiation, and function of both T and B cells, and excessive production of IL-21 has been associated with the development of multiple immune-mediated diseases. Here we review data supporting the involvement of IL-21 in the pathogenesis of SLE.

PMID:
20652041
[PubMed - indexed for MEDLINE]
PMCID:
PMC2905909
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk